Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Sikkerhed og tolerabilitet af en ny implanterbar enhed til behandling af erektil dysfunktion

22. september 2026 opdateret af: Comphya Australia

Sikkerhed og tolerabilitet af en ny implanterbar anordning til behandling af erektil dysfunktion efter radikal prostatektomi

The goal of this clinical trial is to assess if a new device is safe to use as a potential treatment for erectile dysfunction following radical prostatectomy.

The main questions it aims to answer are:

  • Is the device safe?
  • Does the device works well? Are the participants satisfied with the device?

Participants will be implanted with the device during the ongoing prostatectomy surgery and will be asked to complete the following tasks during 6 months follow-up:

  • Come to the hospital for follow-up visits,
  • Complete questionnaires,
  • Activate the device every day,
  • Measure erection hardness.

Researchers will compare an implanted group (participants having the device) with a control group (participants not having the device) to see if the device works well.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

20

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Victoria
      • Fitzroy, Victoria, Australien, 3065
        • St. Vincent's Private Hospital
      • Melbourne, Victoria, Australien, 3050
        • Royal Melbourne Hospital
      • North Melbourne, Victoria, Australien, 3051
        • Australian Prostate Centre
      • Richmond, Victoria, Australien, 3121
        • Epworth HealthCare

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

30 år til 70 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Han

Beskrivelse

Inclusion Criteria:

  • Men of ages between 30-70 years;
  • Men with indication for nerve-sparing prostatectomy surgery;
  • Localised prostate cancer considered suitable for bilateral nerve sparing prostatectomy according to clinical criteria
  • International Index of Erectile Function (IIEF-15) erectile function domain score equal to or greater than 26 prior prostatectomy;
  • Men interested in minimizing the effect of radical prostatectomy on erectile function;
  • Ability to read and understand patient information materials and willingness to sign a written informed consent.

Exclusion Criteria:

  • Men with neurological disease, including a history of spinal cord injury or trauma;
  • IIEF-15 erectile function domain score less than 26 prior prostatectomy;
  • Failure to demonstrate adequate nocturnal erectile function prior prostatectomy;
  • History of erectile dysfunction, priapism and Peyronie disease;
  • History of previous pelvic surgery, trauma or irradiation therapy;
  • Currently have an active implantable device;
  • Patient diagnosed with neurologic degenerative diseases that may negatively impact erectile functions;
  • Identification of technical or clinical limitation to properly apply the use of nerve-sparing techniques during operation;
  • Inability to understand and demonstrate device use instructions;
  • Patients with insulin-dependent diabetes who suffer peripheral neuropathy or other diabetes associated complications;
  • Patient unwillingness to engage in sexual activity;
  • Patient is currently participating in another clinical investigation that would serve as a contraindication to implant a neurostimulator device to augment erectile function;
  • Have participated in any drug or device trial in the last 4 weeks or plan to participate in any other drug or device study during the next 24 months;
  • Possess any other characteristics that, per the investigator's judgment, may increase the risk or impair data collection for the procedure/study;
  • Patient is a member of a vulnerable population (Vulnerable participants include those who lack consent capacity, including the mentally ill, prisoners, cognitively impaired participants, and employee volunteers).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Implanted group

The study device will be implanted during the ongoing prostatectomy surgery. Participants will then be asked to activate it everyday.

The study device is an active implantable device. The device activates the cavernous nerves by delivering electrical pulses, to trigger an on-demand erection. The daily delivery of electrical pulses to the cavernous nerves will also allow participants to recover natural erectile function.

Ingen indgriben: Control group

Participants in the control group will undergo standard prostatectomy and will not be implanted with the study device.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Occurrence of adverse events
Tidsramme: 6 months

Adverse events will be reported using MedDRA terminology.

6 months
Occurrence of surgical complications
Tidsramme: 6 months

Surgical complications will be ranked according to the Clavien-Dindo classification

6 months
Occurrence of device deficiencies
Tidsramme: 6 months

Device deficiencies will be systematically reported and recorded.

6 months
Pain
Tidsramme: 6 months

Patients will be asked to rate pain on a visual analog scale (from 0 to 10)

6 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Objective Device effectiveness
Tidsramme: 6 months

Erectile response obtained when activating the study device will be objectively assessed by measuring penile rigidity with the RigiScan device.

6 months
Subjective Device effectiveness
Tidsramme: 6 months

Erectile function will be subjectively assessed by asking participants to complete validated questionnaires (International Index of Erectile Function, IIEF-15 and Erection Hardness Score, EHS).

6 months
Erectile function recovery
Tidsramme: 6 months

Nocturnal penile erections will be assessed with the RigiScan device. Nocturnal erections reflect the extent of recovery of natural erectile function.

6 months
Delineation of the surgical implantation procedure
Tidsramme: 6 months

The surgeon will record information related to the implantation (duration, position of the device, grading ease of implantation steps, and any comments).

6 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

19. maj 2023

Primær færdiggørelse (Anslået)

30. juni 2028

Studieafslutning (Anslået)

30. juni 2028

Datoer for studieregistrering

Først indsendt

28. november 2022

Først indsendt, der opfyldte QC-kriterier

6. december 2022

Først opslået (Faktiske)

14. december 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

25. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • CP-1.5400

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner